These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
523 related articles for article (PubMed ID: 35090594)
1. Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments. Kumagai S; Koyama S; Itahashi K; Tanegashima T; Lin YT; Togashi Y; Kamada T; Irie T; Okumura G; Kono H; Ito D; Fujii R; Watanabe S; Sai A; Fukuoka S; Sugiyama E; Watanabe G; Owari T; Nishinakamura H; Sugiyama D; Maeda Y; Kawazoe A; Yukami H; Chida K; Ohara Y; Yoshida T; Shinno Y; Takeyasu Y; Shirasawa M; Nakama K; Aokage K; Suzuki J; Ishii G; Kuwata T; Sakamoto N; Kawazu M; Ueno T; Mori T; Yamazaki N; Tsuboi M; Yatabe Y; Kinoshita T; Doi T; Shitara K; Mano H; Nishikawa H Cancer Cell; 2022 Feb; 40(2):201-218.e9. PubMed ID: 35090594 [TBL] [Abstract][Full Text] [Related]
2. The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. Kumagai S; Togashi Y; Kamada T; Sugiyama E; Nishinakamura H; Takeuchi Y; Vitaly K; Itahashi K; Maeda Y; Matsui S; Shibahara T; Yamashita Y; Irie T; Tsuge A; Fukuoka S; Kawazoe A; Udagawa H; Kirita K; Aokage K; Ishii G; Kuwata T; Nakama K; Kawazu M; Ueno T; Yamazaki N; Goto K; Tsuboi M; Mano H; Doi T; Shitara K; Nishikawa H Nat Immunol; 2020 Nov; 21(11):1346-1358. PubMed ID: 32868929 [TBL] [Abstract][Full Text] [Related]
3. Remodeling of the tumor microenvironment via disrupting Blimp1 Dixon ML; Luo L; Ghosh S; Grimes JM; Leavenworth JD; Leavenworth JW Mol Cancer; 2021 Nov; 20(1):150. PubMed ID: 34798898 [TBL] [Abstract][Full Text] [Related]
4. Tumor microenvironment dictates regulatory T cell phenotype: Upregulated immune checkpoints reinforce suppressive function. Kim HR; Park HJ; Son J; Lee JG; Chung KY; Cho NH; Shim HS; Park S; Kim G; In Yoon H; Kim HG; Jung YW; Cho BC; Park SY; Rha SY; Ha SJ J Immunother Cancer; 2019 Dec; 7(1):339. PubMed ID: 31801611 [TBL] [Abstract][Full Text] [Related]
5. Targeting STAT3 Abrogates Tim-3 Upregulation of Adaptive Resistance to PD-1 Blockade on Regulatory T Cells of Melanoma. Huang L; Xu Y; Fang J; Liu W; Chen J; Liu Z; Xu Q Front Immunol; 2021; 12():654749. PubMed ID: 33936081 [TBL] [Abstract][Full Text] [Related]
6. Therapeutic depletion of CCR8 Van Damme H; Dombrecht B; Kiss M; Roose H; Allen E; Van Overmeire E; Kancheva D; Martens L; Murgaski A; Bardet PMR; Blancke G; Jans M; Bolli E; Martins MS; Elkrim Y; Dooley J; Boon L; Schwarze JK; Tacke F; Movahedi K; Vandamme N; Neyns B; Ocak S; Scheyltjens I; Vereecke L; Nana FA; Merchiers P; Laoui D; Van Ginderachter JA J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589525 [TBL] [Abstract][Full Text] [Related]
8. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Duraiswamy J; Kaluza KM; Freeman GJ; Coukos G Cancer Res; 2013 Jun; 73(12):3591-603. PubMed ID: 23633484 [TBL] [Abstract][Full Text] [Related]
9. Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma. Pham CD; Flores C; Yang C; Pinheiro EM; Yearley JH; Sayour EJ; Pei Y; Moore C; McLendon RE; Huang J; Sampson JH; Wechsler-Reya R; Mitchell DA Clin Cancer Res; 2016 Feb; 22(3):582-95. PubMed ID: 26405194 [TBL] [Abstract][Full Text] [Related]
10. An Oncogenic Alteration Creates a Microenvironment that Promotes Tumor Progression by Conferring a Metabolic Advantage to Regulatory T Cells. Kumagai S; Togashi Y; Sakai C; Kawazoe A; Kawazu M; Ueno T; Sato E; Kuwata T; Kinoshita T; Yamamoto M; Nomura S; Tsukamoto T; Mano H; Shitara K; Nishikawa H Immunity; 2020 Jul; 53(1):187-203.e8. PubMed ID: 32640259 [TBL] [Abstract][Full Text] [Related]
11. PD-1 upregulated on regulatory T cells during chronic virus infection enhances the suppression of CD8+ T cell immune response via the interaction with PD-L1 expressed on CD8+ T cells. Park HJ; Park JS; Jeong YH; Son J; Ban YH; Lee BH; Chen L; Chang J; Chung DH; Choi I; Ha SJ J Immunol; 2015 Jun; 194(12):5801-11. PubMed ID: 25934860 [TBL] [Abstract][Full Text] [Related]
12. TOX-expressing terminally exhausted tumor-infiltrating CD8 Han HS; Jeong S; Kim H; Kim HD; Kim AR; Kwon M; Park SH; Woo CG; Kim HK; Lee KH; Seo SP; Kang HW; Kim WT; Kim WJ; Yun SJ; Shin EC Cancer Lett; 2021 Feb; 499():137-147. PubMed ID: 33249194 [TBL] [Abstract][Full Text] [Related]
14. α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas. Dodagatta-Marri E; Meyer DS; Reeves MQ; Paniagua R; To MD; Binnewies M; Broz ML; Mori H; Wu D; Adoumie M; Del Rosario R; Li O; Buchmann T; Liang B; Malato J; Arce Vargus F; Sheppard D; Hann BC; Mirza A; Quezada SA; Rosenblum MD; Krummel MF; Balmain A; Akhurst RJ J Immunother Cancer; 2019 Mar; 7(1):62. PubMed ID: 30832732 [TBL] [Abstract][Full Text] [Related]
15. Near-infrared duocarmycin photorelease from a Treg-targeted antibody-drug conjugate improves efficacy of PD-1 blockade in syngeneic murine tumor models. Fukushima H; Furusawa A; Takao S; Thankarajan E; Luciano MP; Usama SM; Kano M; Okuyama S; Yamamoto H; Suzuki M; Kano M; Choyke PL; Schnermann MJ; Kobayashi H Oncoimmunology; 2024; 13(1):2370544. PubMed ID: 38915782 [TBL] [Abstract][Full Text] [Related]
16. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner. Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370 [TBL] [Abstract][Full Text] [Related]
17. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation. Redin E; Garmendia I; Lozano T; Serrano D; Senent Y; Redrado M; Villalba M; De Andrea CE; Exposito F; Ajona D; Ortiz-Espinosa S; Remirez A; Bertolo C; Sainz C; Garcia-Pedrero J; Pio R; Lasarte J; Agorreta J; Montuenga LM; Calvo A J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658304 [TBL] [Abstract][Full Text] [Related]
18. Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies. Pérez-Ruiz E; Melero I; Kopecka J; Sarmento-Ribeiro AB; García-Aranda M; De Las Rivas J Drug Resist Updat; 2020 Dec; 53():100718. PubMed ID: 32736034 [TBL] [Abstract][Full Text] [Related]
19. PD-1 blockade therapy promotes infiltration of tumor-attacking exhausted T cell clonotypes. Nagasaki J; Inozume T; Sax N; Ariyasu R; Ishikawa M; Yamashita K; Kawazu M; Ueno T; Irie T; Tanji E; Morinaga T; Honobe A; Ohnuma T; Yoshino M; Iwata T; Kawase K; Sasaki K; Hanazawa T; Kochin V; Kawamura T; Matsue H; Hino M; Mano H; Suzuki Y; Nishikawa H; Togashi Y Cell Rep; 2022 Feb; 38(5):110331. PubMed ID: 35108529 [TBL] [Abstract][Full Text] [Related]
20. Preferential accumulation of regulatory T cells with highly immunosuppressive characteristics in breast tumor microenvironment. Syed Khaja AS; Toor SM; El Salhat H; Faour I; Ul Haq N; Ali BR; Elkord E Oncotarget; 2017 May; 8(20):33159-33171. PubMed ID: 28388539 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]